Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cilo Cybin HoldingsJSE:CCC 7 Gross Margin % is 62.57% as of Sep. 2025. GuruFocus rates JSE:CCC with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 943 Drug Manufacturers companies, Cilo Cybin Holdings ranks better than 72.64% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cilo Cybin Holdings had a gross margin of 62.57% for the quarter that ended in Sep. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cilo Cybin Holdings Gross Margin % Related Terms
Cilo Cybin Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cilo Cybin Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:CCC vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cilo Cybin Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cilo Cybin Holdings Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cilo Cybin Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cilo Cybin Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cilo Cybin Holdings (JSE:CCC) has a Gross Margin % of 62.57% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Cilo Cybin Holdings and its competitors. According to the industry distribution chart, Cilo Cybin Holdings ranks #258 out of 943 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Cilo Cybin Holdings' Gross Margin % too high?
Cilo Cybin Holdings' current Gross Margin % is 62.57%. The Drug Manufacturers industry median Gross Margin % is 48.54. Cilo Cybin Holdings' value of 62.57% is 28.9% above this industry median. Based on the distribution chart, Cilo Cybin Holdings ranks #258 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cilo Cybin Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Cilo Cybin Holdings' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cilo Cybin Holdings ranks #258 out of 943 companies for Gross Margin %. This puts Cilo Cybin Holdings in the upper half of its industry. The industry median Gross Margin % is 48.54. Cilo Cybin Holdings' value of 62.57% is 28.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cilo Cybin Holdings's current Gross Margin % of 62.57% is 28.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cilo Cybin Holdings and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cilo Cybin Holdings's current Gross Margin % is 62.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cilo Cybin Holdings stock overvalued right now?
Cilo Cybin Holdings (JSE:CCC) has a current Gross Margin % of 62.57%. The current Gross Margin % is 62.57% and 28.9% above the Drug Manufacturers industry median of 48.54. Cilo Cybin Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cilo Cybin Holdings (JSE:CCC), the current Gross Margin % is 62.57% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cilo Cybin Holdings Ltd is engaged in identifying viable investments in Biotech, Biohacking and Pharmaceutical businesses. It offers products and services in the medical cannabis sector.
7GF Score
Get the complete analysis for JSE:CCC
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:CCC has been successfully added to your 
